目前,针对免疫检查点阻断的药主要是PD-1/PD-L1为主,国内也有多家药企宣布了相关的临床试验,但其他免疫检查点如LAG-3, IDO抑制剂、CD137、CD134等,这些都是我们可以开拓新的方向。同时目前主要研究都集中在单克隆抗体的研发,而关于免疫检查点阻断的小分子化学药物报道不多,考虑到小分子在药物动力学性质方面的众多优点,在单一疗法和其它组合方案里表现出的更大灵活性,可为患者和医生提供一个新的治疗选择。参考文献:[1] Brignone, C., et al., IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines, 2007. 5: p. 5.[2] IMP321 as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma.(https://clihttps://clinicaltrials.gov/ct2/show/NCT02614833?term=AIPAC&recrs=ab&rank=1)[3] Phase 1 Study of IMP321 Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma (TACTI-mel).https://clinicaltrials.gov/ct2/show/NCT02676869?term=Tactimel&recrs=ab&rank=1)[4] Prima BioMed announces new IP for its Lead IMP321 Development Program. (www.primabiomed.com.au/investor/pm/2015/1347.php)[5] A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis. (https://clinicaltrials.gov/ct2/show/NCT02195349版权声明/免责声明本文为授权转载作品,仅供感兴趣的个人谨慎参考,非商用,非医用、非投资用。版权归拥有者!衷心感谢!文中图片取自网络,根据CC0协议使用,版权归拥有者。任何问题,请与我们联系。衷心感谢!